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Epo and Non-hematopoietic Cells: What Do We Know?
Omolara O. Ogunshola and Anna Yu. Bogdanova
Abstract
The hematopoietic growth factor erythropoietin (Epo) circulates in plasma and controls the oxygen carrying 
capacity of the blood (Fisher. Exp Biol Med (Maywood) 228:1–14, 2003). Epo is produced primarily in 
the adult kidney and fetal liver and was originally believed to play a role restricted to stimulation of early 
erythroid precursor proliferation, inhibition of apoptosis, and differentiation of the erythroid lineage. 
Early studies showed that mice with targeted deletion of Epo or the Epo receptor (EpoR) show impaired 
erythropoiesis, lack mature erythrocytes, and die in utero around embryonic day 13.5 (Wu et al. Cell 
83:59–67, 1995; Lin et al. Genes Dev. 10:154–164, 1996). These animals also exhibited heart defects, 
abnormal vascular development as well as increased apoptosis in the brain suggesting additional functions 
for Epo signaling in normal development of the central nervous system and heart. Now, in addition to its 
well-known role in erythropoiesis, a diverse array of cells have been identiﬁed that produce Epo and/or 
express the Epo-R including endothelial cells, smooth muscle cells, and cells of the central nervous system 
(Masuda et al. J Biol Chem. 269:19488–19493, 1994; Marti et al. Eur J Neurosci. 8:666–676, 1996; 
Bernaudin et al. J Cereb Blood Flow Metab. 19:643–651, 1999; Li et al. Neurochem Res. 32:2132–2141, 
2007). Endogenously produced Epo and/or expression of the EpoR gives rise to autocrine and paracrine 
signaling in different organs particularly during hypoxia, toxicity, and injury conditions. Epo has been 
shown to regulate a variety of cell functions such as calcium ﬂux (Korbel et al. J Comp Physiol B. 174:121–
128, 2004) neurotransmitter synthesis and cell survival (Velly et al. Pharmacol Ther. 128:445–459, 2010; 
Vogel et al. Blood. 102:2278–2284, 2003). Furthermore Epo has neurotrophic effects (Grimm et al. Nat 
Med. 8:718–724, 2002; Junk et al. Proc Natl Acad Sci U S A. 99:10659–10664, 2002), can induce an 
angiogenic phenotype in cultured endothelial cells and is a potent angiogenic factor in vivo (Ribatti et al. 
Eur J Clin Invest. 33:891–896, 2003) and might enhance ventilation in hypoxic conditions (Soliz et al. J 
Physiol. 568:559–571, 2005; Soliz et al. J Physiol. 583, 329–336, 2007). Thus multiple functions have 
been identiﬁed breathing new life and exciting possibilities into what is really an old growth factor.
This review will address the function of Epo in non-hematopoietic tissues with signiﬁcant emphasis on 
the brain and heart.
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Epo expression is hypoxia inducible and regulation occurs via the 
hypoxia responsive element (HRE) present in the 3¢ region of the 
gene which is bound by heterodimeric transcription factors namely 
hypoxia-inducible factors (HIFs). Three members of the HIF tran-
scription factor family HIF-1, -2, and -3 have now been identiﬁed. 
HIF-1 was discovered in 1991 by its ability to bind and stimulate 
transcription of the Epo gene during hypoxia (16, 17) and for sev-
eral years, was assumed to be the primary stimulus for Epo produc-
tion in response to acute hypoxia. Later a second hypoxia-inducible 
transcription factor termed HIF-2 was discovered (18–20). 
Subsequent data from in vivo (21) and in vitro (22) experiments 
suggested that despite the fact that HIF-1 clearly binds the HRE 
of the Epo gene in response to hypoxia and both have the potential 
to bind many of the same genes, in vivo HIF-2 is the primary 
mediator of Epo expression in kidneys in response to hypoxia. In 
agreement downregulation of HIF-2 in the brain, but not HIF-1, 
drastically reduced hypoxia-induced Epo expression (23) and more 
recently Haase and colleagues (24) clearly demonstrated the pri-
mary role of HIF-2 in promoting the hypoxic renal Epo response.
The HIFs are heterodimers composed of a constitutively 
expressed b subunit (also known as aryl hydrocarbon receptor 
nuclear translocation, ARNT) and an oxygen-regulated a subunit 
(reviewed by ref. 25–27). Regulation of HIF activity occurs at dif-
ferent levels including protein stability, phosphorylation, nuclear 
translocation, and activity, all being inﬂuenced by alterations in 
oxygen levels. Under normoxic conditions the a subunit is 
degraded. In contrast, under hypoxic conditions the a subunit is 
stabilized and translocated to the nucleus where it dimerizes with 
ARNT and subsequently binds to hypoxic binding sites (HBS) of 
target genes. The HBS is a conserved consensus sequence (A/G)
CGTG within the HRE present in oxygen-regulated target genes 
involved in cell survival, glycolysis, angiogenesis, erythropoiesis, 
and iron metabolism (25). Degradation of HIF-a is triggered by 
oxygen-dependent hydroxylation of proline residues located in the 
oxygen-dependent degradation domain by a family of prolyl 
hydroxylases, namely PHD1, PHD2, and PHD3. These enzymes 
are speciﬁc HIF prolyl hydroxylases that require Fe(II) as a cofac-
tor as well as oxygen and 2-oxoglutarate as co-substrates (28, 29). 
Prolyl hydroxylation promotes the recruitment of the tumor sup-
pressor protein von Hippel Lindau, which is part of the E3 ligase 
ubiquitination complex, priming HIFs for degradation in the pro-
teosomes (reviewed by ref. 30, 31).
Other regulatory elements in the 5¢ promoter of the Epo 
gene include a highly conserved GATA sequence as well as NFkB 
binding motifs (32, 33). Both these sites seem to have inhibitory 
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effects on Epo expression. The GATA site preferentially binds the 
transcription factor GATA-2, which has been reported to inhibit 
Epo gene expression (34, 35). NFkB binding to a site adjacent to 
the minimal HRE of the Epo promoter also inhibits Epo expression. 
Although activities of GATA-2 and NFkB in HepG2 cells decrease 
in hypoxia compared to normoxia conditions both transcription 
factors were shown to be involved in the suppression of Epo gene 
expression by IL-1b and TNFa (35). Thus these pathways may 
be responsible for impaired Epo synthesis in a variety of 
inﬂammatory diseases and cancers.
Hypoxia and anemia are major events known to induce Epo gene 
expression, however it should be noted that many different injury 
stimuli are being shown to induce Epo expression (36, 37). Once 
the signals are transduced erythropoietin is released into the circu-
lating blood ﬂow and ﬁnally binds cells expressing the Epo recep-
tor (EpoR).
The EpoR is a member of the type 1 superfamily of single-
transmembrane cytokine receptors (38, 39). Expression of the 
EpoR is located to progenitor cells from hematopoietic, endothe-
lial, skeletal muscle, and neuronal compartments (40–42). EpoR is 
downregulated during differentiation of erythroid cells and not 
expressed on mature red blood cells or skeletal muscle. Interestingly, 
despite being signiﬁcantly downregulated in developing neuronal 
tissues until embryonic day 17, EpoR expression persists in select 
vascular and neuronal compartments. Indeed EpoR has been 
observed in brain during development and adulthood in humans 
and other mammals (37, 43–46). More recent studies have dem-
onstrated expression of EpoR on cells from a variety of tissues 
including heart (47), kidney (48), pancreas (49), and uterus (50).
Erythropoiesis is stimulated by generating a complex network of 
molecular signals involved in the control of cell proliferation, differ-
entiation, and death. EpoR homodimers are expressed on the eryth-
roid progenitor cell surface (51) and binding of Epo to the EpoR 
triggers conformational changes in the receptor extracellular domain 
that consequently activates JAK2 by autophosphorylation (52, 53). 
JAK2 activation results in the phosphorylation of tyrosine residues on 
the cytoplasmic region of EpoR and recruits a variety of Src homol-
ogy-2 (SH2) domain-containing proteins that initiate downstream 
cascades via different signaling pathways including signal transducer 
and activator of transcription (STAT), phosphatidylinositol-3 kinase 
2 Epo-R Is Expressed Multiple Tissues
3 Classical Erythroid EpoR Signaling
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(PI3K)/Akt (also known as protein kinase B) and mitogen-activated 
protein kinase (MAPK) (54, 55). Although Epo can activate STAT1, 
STAT3, and STAT5a/b, JAK2/STAT5 is the classical pathway acti-
vated in erythroid cells (summarized in Fig. 1 and reviewed in ref. 56. 
Epo-mediated activation of this pathway leads to the upregulation of 
the antiapoptotic Bcl2 and Bcl-XL gene, thereby protecting precur-
sors from apoptosis (56, 57).
The PI3K/Akt pathway has been shown to be necessary, but 
not solely sufﬁcient, for erythroid cell survival by protecting them 
from apoptosis (58). The PI3K/Akt cascade phosphorylates serine 
residue 310 of GATA-1 both in vitro and in erythroid cells thereby 
enhancing GATA-1 transcriptional activity (55). GATA-1 binds to 
a consensus GATA motif present in the cis-regulatory elements of 
most erythroid genes and is a key transcription factor for antiapop-
totic Bcl-XL and erythroid-speciﬁc gene transcription, and terminal 
differentiation of erythroid precursor into red blood cells (59–61). 
Notably PI3K can also be indirectly recruited to EpoR by other 
proteins such as Grb-2. PI3K-mediated Akt phosphorylation inhib-
its cytochrome c release from mitochondria (62) and facilitates 
NFkB activation by enhancing inhibitor of NF-kappaB (IkB) deg-
radation (63). Additionally, Akt can inhibit activity of Foxo3A 
Fig. 1 Downstream pathways activated by Epo signaling in hematopoietic and non-hematopoietic cells. In 
non-hematopoietic cells the bCR subunit makes a functional receptor with a classic EpoR. In the absence of 
bCR it is postulated that the homodimer conﬁguration will occur. Note the similarities of the downstream 
pathways activated by both hetero and homodimers
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thereby downregulating its targets proteins having antiproliferative 
or proapoptotic functions (64, 65).
Another important Epo-mediated signaling pathway is the 
MAPK pathway. MAPKs are serine/threonine kinases activated by 
extracellular signals of which there are at least three distinct types: 
the classical ERK1/ERK2 kinases, the p38MAPKs (p38), and the 
stress-activated protein kinase/Jun kinase (SAPK/JNK) subfamily. 
All play important roles in Epo-induced differentiation or apoptosis 
(66–70).
Soon after stimulation of the receptor by its ligand, mechanisms 
integral to downregulation of these signaling pathways are also acti-
vated, returning signaling proteins to their basal levels (see Fig. 2, 
pathway 8). This process is crucial to prevent hyperstimulation and, 
consequently, the dysregulation of cellular machinery (reviewed in 
ref. 63). Notably, EpoR is also synthesized in a soluble form (sEpoR) 
that corresponds to the extracellular domain of the complete receptor 
as a result of alternative splicing of EpoR mRNA (71). The sEpoR is 
secreted into the extracellular ﬂuid and acts as a sink, sequestering 
Epo and preventing its ability to activate EpoR and downstream sig-
naling cascades (see Fig. 2, pathway 8). The presence of sEpoR has 
been reported in plasma and several tissues including liver, spleen, 
kidney, heart, brain, and bone marrow (15, 72).
Production of Epo and expression of the EpoR has been detected in 
non-hematopoietic tissues and emerging evidence suggests that Epo 
exerts cytoprotective effects on non-erythroid cells. Notably, a tissue-
speciﬁc degree of Epo regulation has been reported. Depending on 
the severity of hypoxia, Epo mRNA levels can increase up to 20-fold 
in the brain in contrast to 200-fold in the kidney (5) and remain 
high much longer (73). Also brain Epo, puriﬁed from primary ner-
vous cell cultures, was shown to have lower molecular weight and be 
more active than recombinant Epo and serum Epo at low concentra-
tions (74). Importantly, tissue protection in vivo and in vitro appears 
to require nanomolar concentrations of Epo that are not normally 
reached in the circulation, in contrast to low picomolar concentra-
tions required for erythropoiesis (75) underlining the fact that para-
crine/autocrine signaling likely results in high local concentrations 
of Epo. The EpoR expressed by brain (PC12) cells also had lower 
afﬁnity than EpoR on erythroid cells and required different acces-
sory proteins compared to erythrocyte precursors (4). Lower bind-
ing afﬁnities of EpoR expressed by non-erythroid cells was also 
reported in humans (76). Thus, differential activity and receptor 
afﬁnity allows speciﬁc activation of erythroid and non-hematopoietic 
receptors thus preventing crosstalk between the endocrine and para-
crine systems of Epo.
4 Epo and EpoR Signaling in Non-hematopoietic Tissues
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The functional EpoR that attenuates tissue damage is not nor-
mally, or only weakly, expressed in most tissues and is strongly 
induced following injury (36, 37). EpoR expression level and the 
number of receptors per cell is signiﬁcantly lower than observed in 
erythropoetic precursor cells and for that reason was reported as 
Fig. 2 Schematic representation of the multiple putative cytoprotective effects of Epo in non-erythropoietic 
tissues. Interaction of blood-borne Epo with heterodimeric Epo receptors on endothelial cells activates the 
PI3K-Akt pathway (1 ) leading to NO production by eNOS and its translocation to the periphery where it induces 
cytoprotective effects (2 ). Another second messenger known to be released by endothelial cells upon their 
stimulation with Epo is endothelin 1 (ET-1) which also elicits its protective effects in peripheral cells (3 ). 
Further targets of circulating Epo are blood cells, including red blood cells and macrophages. Similar to 
endothelial cells, Epo binding to red blood cells triggers production of NO by eNOS (4 ). Endothelial precursor 
cells (EPCs) are very sensitive to Epo. Epo controls their number, recruitment to the site of injury, homing, and 
the quality of resulting mature endothelial cells (5 ). Peripheral cells were shown to respond to Epo stimulation 
directly. Blood vessels are largely impermeable for Epo when undamaged. However the blood-tissue barrier is 
less tight in capillaries and although leakage of Epo from the capillary system into the peripheral tissue has 
never been demonstrated convincingly, it cannot be excluded (6 ). Alternatively, peripheral cells may produce 
their own Epo. Indeed induction of Epo expression has been demonstrated in hypoxic brain and heart. Thus 
once produced the cytokine is released causing autocrine and paracrine effects (7 ). Action of Epo is transient 
and the cytokine is internalized and degraded upon its binding to the receptor. Free Epo pools in the plasma 
may also be regulated by sequestration by the circulating soluble Epo receptor (8 ). For more details of these 
mechanisms please see main text
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“undetectable” in one publication (77) - an opinion not shared by 
the majority of researchers working in the ﬁeld (78). Recent data 
advocates that the tissue protective non-hematopoietic receptor is 
distinct from the hematopoietic receptor responsible for erythro-
poiesis being a heterodimer consisting of the beta common recep-
tor subunit (bCR also known as CD131) in combination with the 
EpoR subunit (see Fig. 1 and reviewed by ref. 75). A variety of 
tissues have been found to express bCR and EpoR including the 
central and peripheral nervous system, retina, heart, kidney, mus-
cle, and endothelium. Notably, the important role of the bCR in 
Epo-mediated protection has been demonstrated in brain injury 
models using bCR knockout mice (79, 80) as well as in endothe-
lium using siRNA technology (81). However the downstream 
signaling mechanisms activated by bCR are still to be elucidated. 
When EpoR is not colocalized with bCR it presumably self-associates 
forming the classical EpoR homodimer that also supports signaling 
(reviewed by ref. 75).
The importance of EpoR speciﬁcally in non-hematopoietic tis-
sues has been recently investigated using transgenic mice with EpoR 
expression restricted to hematopoietic tissues and the vascular 
endothelium. These mice survive without any gross abnormalities 
but become obese and insulin resistant due to loss of Epo regula-
tion of energy homeostasis (82). It should be noted however that 
because endothelial cells have the same origin as hematopoietic cells 
these mice still express EpoR on vascular endothelium. Recent stud-
ies using these mice in heart ischemia–reperfusion injury model 
(83) and traumatic brain injury model (84) identify the endothe-
lium as a major contributor to Epo-mediated protection and sup-
porter of signiﬁcant tissue recovery from injury. More experiments 
are now needed in various injury paradigms to better understand 
the contribution of the homoreceptor, heterodimer, and the 
endothelium per se to tissue protection during Epo treatment.
Epo and EpoR have been detected during early brain development 
in rodent models. Both are also expressed during human fetal devel-
opment starting around 7 weeks and increase from 8 to 24 weeks 
(43). After birth Epo was detected in human cerebral spinal ﬂuid 
and found to be induced by hypoxia (5). Notably, Epo and EpoR 
expression persist in the human brain throughout adulthood.
Mouse models showed that knockout of either gene caused 
embryonic death not only due to erythropoiesis failure but also as 
a result of compromised brain development. In these models the 
neurons exhibited intrinsic defects such as slowed proliferation and 
increased sensitivity to hypoxic stress (85). Additionally a speciﬁc 
deﬁcit in post-stroke neurogenesis by the impaired migration of 
5 Brain
5.1 Endogenous 
Production of Epo  
in CNS
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NPC to the peri-infarct cortex was also observed in adult mice 
stroke models. Thus a clear role for coordinated Epo signaling in 
early brain development is evident.
Different neural cells express Epo and the EpoR including neu-
rons, astrocytes, and oligodendrocytes (6, 74, 86, 87). Epo appears 
to be mainly produced by astrocytes (4, 88), while EpoR is 
expressed by neurons (43). During injury however it seems all cells 
are capable of upregulating the Epo signaling cascade eliciting both 
autocrine and paracrine effects (see Fig. 2, pathway 7).
Epo was shown to protect neurons from hypoxic and toxic 
insults in different cell culture and ex vivo models (see Fig. 2, path-
way 6). Epo supplementation counteracted hypoxia-induced cell 
death in cortical and hippocampal neurons (89–91) and protected 
PC12 cells from serum withdrawal (92). In toxicity models Epo 
pretreatment protected hippocampal and cortical neurons from 
glutamate (93) and NMDA exposure (46), ketamin cytotoxicity 
(94), kainate-induced excitocytotoxicity in cultured spinal neurons 
(95), as well as SH-SY5Y neuroblastoma cells from staurosprine-
induced cell death (96) to name but a few. Supplementation of 
Epo also increased neuronal survival during oxygen glucose depri-
vation, the in vitro model for hypoxic-ischemia (88). Epo has also 
been suggested to contribute to myelin recovery by enhancing 
generation, proliferation, and differentiation of oligodendrocytes 
after ischemic injury (97, 98) and inﬂammatory injury (99).
Generally Epo protects neuronal cells by regulating the balance 
between proapoptotic and antiapoptotic pathways. Similar to eryth-
roid cells, a major mechanism occurs through JAK2/STAT activa-
tion and induction of PI3K/Akt pathways that inhibit the 
pro-apoptotic protein Bad and prevent release of cytochrome c and 
caspase activation (see Fig. 1). Akt activation also inhibits glycogen 
synthase kinase 3 (GSK3) (94) resulting in inhibition of the mito-
chondrial permeability transition pore, a major determinant of cell 
death, through caspase activation. However inhibition of Akt only 
partially prevented neuroprotection suggesting the contribution of 
additional signaling mechanisms (89). A unique pathway for Epo-
mediated neuroprotection in the brain seems to be induction of 
crosstalk between JAK2 and NFkB signaling cascades (see Fig. 1). 
EpoR mediated activation of Jak2 led to phosphorylation of IkB, 
subsequent nuclear translocation of NFkB, and NFkB-dependent 
transcription of neuroprotective genes (88, 100). Accordingly trans-
fection of cerebrocortical neurons with a dominant interfering form 
of Jak2, or an IkB super-repressor, blocked Epo-mediated preven-
tion of neuronal apoptosis. Epo can also modulate the activity of 
calcium channels through phospholipase C (PLC) (101), thereby 
reducing the release of excitatory neurotransmitters and augmenting 
nitric oxide production (92, 102). Very recent data suggests that 
Epo-mediated neuroprotection is also associated with increased 
5.2 Neuroprotection 
by Epo In Vitro
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TIMP-1 activity and decreased MMP-9 activity in vivo and in vitro, 
and can be reversed by inhibition of JAK-2 or TIMP-1 (103).
A couple of studies have recently implicated Epo to be a medi-
ator of the protective effects of nitric oxide (NO) in neurons. Loss 
of EpoR coincided with programmed cell death in neurons (104). 
Neuronal NO was induced during hypoxia and correlated with 
protection in control cells but not increased in neurons that lacked 
the EpoR. However when treated with a neuronal nitric oxide syn-
thase (nNOS) inhibitor the neurons lost their ability to induce 
EpoR expression in hypoxia and thus were not protected (104). In 
line with this ﬁnding another study demonstrated that nNOS 
knockout mice are more susceptible to peripheral neuropathy than 
their wild type counterparts due to the absence of NO-mediated 
activation of HIF-1 and subsequent downstream neuroprotection 
by Epo (105). Ex vivo experiments showed that protection recov-
ered by using low doses of NOS donors was almost completely 
abrogated by Epo siRNA. Thus it appears the neuroprotective 
effect of Epo, as well as EpoR expression on neural cells, may also 
be regulated by NO.
Intriguingly, what determines the speciﬁc pathways activated 
by Epo, or the coordination of these multiple cascades, remains till 
now unknown.
Different animal models have suggested potential clinical uses of 
Epo to combat ischemia or trauma. Cerebroventricular infusion of 
Epo was shown to reduce ischemia-induced learning disabilities 
and rescue hippocampal CA1 neurons from lethal ischemic damage 
in gerbils whereas infusion of EpoR abolished neuroprotection. 
In various mouse and rat models of ischemia, intracerebral injection 
of Epo also attenuated brain damage by reducing infarct volume 
by up to 50% (6, 106, 107) and improved cognitive function 
(108–110). This was further underlined by the fact that cerebral 
administration of soluble EpoR reduced the protective effect of 
hypoxia preconditioning by up to 80% in other models (111, 112). 
Overall exogenous Epo administration (see Fig. 2, pathway 6) has 
been shown to be protective in multiple cerebral tissue injuries 
including neonatal ((113) and reviewed by ref. 114, 115) or adult 
rodent focal brain ischemia, brain trauma (116), animal models 
of multiple sclerosis (117, 118) as well as spinal chord injury 
(119, 120). Increased oligodendrogenesis and attenuated 
proinﬂammatory cell inﬁltration was also observed in mouse mod-
els of EAE suggesting Epo positively stimulates oligodendrogen-
esis and reduces the autoimmune response (117, 118). In the 
neonatal brain, Epo signiﬁcantly reduced white matter damage 
during hypoxia/ischemia and increased oligodendrogenesis and 
maturation of oligodendrocytes despite being applied in a delayed 
manner (113). Notably, in models of prolonged hypoxia, Epo 
secretion from astrocytes was shown to play an important role in 
5.3 Neuroprotection 
by Epo In Vivo
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neuronal survival (4, 5) highlighting the paracrine functions of 
Epo (see Fig. 2, pathway 7).
Mechanistically Epo reduced infarct volume via JAK2, ERK, 
and PI3K/Akt pathways by elevating Bcl-xL and lowered both 
neuronal and inducible NOS levels in neurons (121). Upregulation 
of anti-apoptotic pathways was also observed in neonatal rodents 
submitted to focal cerebral ischemia (122). Epo-induced VEGF 
and BDNF have also been suggested to have an important role in 
angiogenesis- and neurogenesis-associated brain repair in rats 
treated with Epo after embolic stroke (110) similar to observations 
from in vitro studies (123). Epo was also shown to inhibit iNOS 
expression preventing the formation of excess NO and protecting 
facial motor neurons from death (97).
As in other neural cells Epo protects retina against cell death 
during injury but in contrast to other CNS regions where basal Epo 
is located mainly to astrocytes (4, 86), retinal neurons may express 
both Epo and EpoR (12). Epo prevented death of neurotrophic 
factor-deprived rat RGCs in vitro, rescued axotomized RGCs in vivo, 
and prevented caspase-3 activation (124). Recently it was demon-
strated that exogenous Epo signiﬁcantly attenuates retinal neuronal 
cell death induced by glyoxal-AGEs by promoting antiapoptotic and 
suppressing apoptotic proteins (125). Systemic administration of 
Epo before or immediately after retinal ischemia reduced histopatho-
logical damage and promoted functional recovery (12). When given 
therapeutically after light insult, Epo also mimicked the effect of 
hypoxic preconditioning by crossing the blood-retina barrier and 
preventing light-induced apoptosis via caspase-1 activation interfer-
ence (11). Although transgenic overexpression of Epo with consti-
tutively high levels of Epo in the retina protected photoreceptors 
against light-induced degeneration, the course or extent of retinal 
degeneration in genetic models was unaltered suggesting different 
apoptotic mechanisms exist (126).
Overall current evidence suggests that similar to erythroid 
cells, and as indicated by in vitro studies, phosphorylation of JAK-2 
is the initial step in Epo-mediated protection in the injured brain 
(9). Subsequently, downstream signaling modulates the transcrip-
tion and activity of proteins involved in cell survival.
In contrast to its neuroprotective properties, putative regenera-
tion-enhancing effects of Epo have been less well studied. Epo was 
ﬁrst shown to augment the activity of choline acetyltransferase in 
central cholinergic neurons in vitro and in vivo (127) and to 
enhance dopamine generation and differentiation of neuronal pre-
cursors in hypoxia. In agreement Epo was demonstrated to act 
directly on neural stem cells and promote the production of neu-
ronal progenitors in forebrain (42) thus suggesting a direct contri-
bution to neurogenesis after hypoxia. Epo-related functional 
recovery after spinal cord injury has also been described (119) and 
5.4 Neurotrophic 
Effects of Epo
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correlated with behavioral improvements following Epo treatment 
(120). During stroke models Epo also signiﬁcantly improved neu-
rogenesis and functional recovery by increasing cerebral BDNF 
levels (110). Epo also enhanced oligodendrogenesis (117) and 
recovery of neurological function after neonatal hypoxic/ischemic 
brain (113). In the retina, Epo promoted neurite extension from 
postnatal retinal ganglion cells in vitro (128), induced Jak2/Stat3 
phosphorylation and activated PI3K/Akt (see Fig. 1). Inhibition 
of Jak2/Stat3 abolished Epo-induced growth verifying the path-
way is involved in conferring regeneration-enhancing Epo func-
tions in the retina (129).
Thus the positive effects of Epo are not limited to neuropro-
tection but extend to neurogenesis and differentiation. Indeed 
more research needs to be performed in this area.
Studies using Epo to combat brain disease progression have been 
largely encouraging. In 2002 the Göttingen Epo stroke pilot study 
demonstrated the neuroprotective effectiveness of Epo in human 
stroke patients (130). Epo-treated patients showed signiﬁcantly 
better recovery than the control group regarding the clinical out-
come parameters, the evolution of infarct size, and the proﬁle of 
circulating damage markers. Disappointingly, the recent German 
multicenter Epo Stroke Trial revealed an increased risk of serious 
complications such as death, intracerebral hemorrhage, brain 
edema, and thromboembolic events (131). This study emphasized 
the point that when used in combination with other drugs (in this 
case recombinant tissue plasminogen activator used for hemodialy-
sis) Epo may even be detrimental for patient outcome. Epo therapy 
was effective in reducing progressive atrophy and loss of gray mat-
ter in patients diagnosed with schizophrenia (132). Also in healthy 
volunteers Epo improved cognitive and neural processing of emo-
tional information showing similar effects to those of serotonergic 
and noradrenergic antidepressant drugs (133). Together these tri-
als suggest future clinical applications for Epo in the treatment of 
psychiatric disorders characterized by cognitive dysfunction. 
During the ﬁrst phase I/IIa study of high dose Epo treatment in 
patients with chronic progressive multiple sclerosis signiﬁcant 
improvement in clinical and electrophysiological motor function as 
well as cognitive performance was achieved (134). Epo treatment 
also somewhat improved outcome for patients after subarachnoid 
hemorrhage (135). However, in contrast, the ﬁrst randomized trial 
of Epo in moderate traumatic brain injury patients during the 
resuscitative phase showed Epo did not reduce neuronal cell death 
compared to placebo and disappointingly injury severity was worse 
in the Epo group (136).
Many of the clinical studies performed show promise however 
they also have a number of limitations. For example frequently the 
patient numbers have been small and some of the studies not blind. 
5.5 Epo in Treatment 
of Brain Diseases
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Also the doses used in the different injury paradigms as well as the 
routes of administration vary considerably. The mechanisms that 
improve function, enhance regeneration and/or slow deteriora-
tion remain undetermined and similarly the reasons why some 
studies have been less successful or even failed is also unclear. 
Indeed many questions remain open and the jury is out as to 
whether Epo will fulﬁll its putative potential - based on animal 
studies - to be a “universal” therapy for brain diseases.
Epo is important during myocardial development and knockdown 
of Epo or EpoR in mice results in reduction in the number of car-
diomyocytes (hypoplasia) and enhanced susceptibility to left ven-
tricular dilatation and cardiac death (137, 138). However this 
phenotype may be largely rescued by restoration of EpoR produc-
tion in hematopoietic tissue (139). Attempts to localize the EpoR 
within the heart have been made by dissecting of chick embryonic 
heart into epicardium, myocardium, and endocardium (140). 
These experiments revealed that endogenous Epo is most likely 
produced by the epicardium whereas EpoR is present in embry-
onic myocardium. However, positive inotropic and lusitropic 
effects of Epo have been later recorded in isolated human epicar-
dial stripes indicating that adult human and mouse epicardium 
responds to Epo (141). Changes in contractile force, but not in 
contractile rate, were reported for isolated denervated rat heart 
perfused with Krebs-Henseleits saline (142).
Epo receptors and functional responses to Epo were shown in iso-
lated cardiomyocytes (141, 143–146) coronary endothelial cells 
(83, 147) and ﬁbroblasts (148). The cardiac EpoR was shown to 
respond equally efﬁciently to Epo, carbomylated Epo (CEPO), and 
ARA-290 (141, 149, 150), a synthetic Epo mimetic comprised only 
of helix B part of the cytokine. This synthetic non-erythropoietic 
peptide was shown to activate the heteroreceptor, composed of an 
EpoR subunit and bCR, but not the classical EpoR homodimer 
(79). These ﬁndings suggest that the effects of Epo in the heart are 
most likely mediated by such a heteroreceptor. Indeed expression of 
bCR in the heart and the lack of Epo effect in bCR knockout myo-
cardium was shown (79). Whereas in hematopoietic lineage EpoR 
expression is induced by GATA-1, Sp1, and Wt1 transcription fac-
tors (151, 152), expression of the common EpoR subunits in the 
heart is under control of GATA-4 and Sp1 transcription factors 
(145). The role of Wt1 expressed only in epicardium in regulation 
of EpoR expression remains to be clariﬁed (153). Induction of 
EpoR expression has been observed in the failing ischemic heart 
and is most likely linked to the stabilization of HIF that is down-
6 Heart
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regulated in aging tissues. In agreement heat-induced stabilization 
of HIF1a in the heart is also associated with an increase of EpoR in 
the heart (151). Thus down-regulation of various transcription fac-
tors may reduce the efﬁciency of myocardial Epo treatment. Changes 
in EpoR expression during myocardial development and as a func-
tion of age remain to be investigated. Regulators of expression of 
bCR in the heart have also not been studied.
The source of Epo for receptor activation in the myocardium 
remains unknown. Plasma-borne Epo most likely does not reach 
cardiomyocytes (147). Thus, the cytokine should be generated by 
one or more cell types within the myocardium and then be released 
for autocrine/paracrine receptor activation similar to that in the 
brain (Fig. 2, pathway 7). In zebraﬁsh, heart and liver were shown 
to be the major Epo-producing organs (154). Although myocar-
dial Epo expression may be induced by hypoxic exposure (155) the 
origin of endogenous Epo secreting cells in the mammalian heart 
is unknown.
Localization of Epo action depends on the route of its admin-
istration/secretion. When applied intravenously Epo interacts 
primarily with EpoR of endothelial cells of coronary vessels (Fig. 2, 
pathway 1) (83, 147). Thereby, cardioprotection of the plasma-
borne Epo is mediated by factors secreted from the endothelium 
upon activation of endothelial EpoR (Fig. 2, pathways 2 and 3). 
Amongst these factors are endothelin-1 and NO (156). When 
applied directly to isolated cardiomyocytes, Epo was shown to pro-
mote mitogenesis of neonatal cardiomyocytes, affect Ca2+ handling 
in isolated cells causing an increase in the amplitude and reduction 
in duration of calcium transients, and protecting them from oxida-
tive stress and doxorubicin-induced apoptosis (Fig. 2, pathways 6 
and 7) (141, 157–159).
An exhaustive overview of the molecular mechanisms of cardio-
protective effects of erythropoietin can be found in recent reviews 
(160–162). As mentioned above, the cardiac-speciﬁc receptor is 
most likely a heterodimer. The downstream elements of signaling 
cascades induced by activation of such a heteroreceptor remain 
largely unknown. Also current data on the molecular mechanisms 
of the cardioprotective action of Epo comes from observations of 
the downstream effects of Epo in the heart. This is characteristic of 
most of the studies performed to date in which observations ﬁt into 
the pre-existing model of homodimer function in erythroid precur-
sor cells (see Fig. 1). To what extent activation pathways for the 
homo- and heterodimer are similar remains unknown.
Several studies indicated that the action of Epo in the heart is asso-
ciated with activation of PI3K-Akt pathway with subsequent 
 up-regulation of NO production (83, 160, 163, 164). Endothelial 
NO synthase (eNOS) is localized in the caviolae of cardiomyocytes 
6.3 Where Does Epo 
Act and What Are Its 
Targets?
6.3.1 Acute Responses: 
PI3-Akt-eNOS Signaling
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and is known to regulate the activity of l-type calcium channels by 
phosphorylation and S-nitrosylation. Upon eNOS activation and 
NO binding to soluble guanylyl cyclase, PKG-induced phosphory-
lation of contractile protein machinery is induced (165). These 
effects of Epo were conﬁrmed for isolated cells as well as in vivo in 
hearts after intravenous Epo administration. In the latter case Akt 
and eNOS phosphorylation is restricted to the endothelial cells of 
coronary vessels (147). In cardiomyocytes the direct cytoprotective 
effect of Epo is mediated by its regulatory action on calcium han-
dling and stabilization of the mitochondria. Epo induces activation 
of eNOS in cavioli by its phosphorylation at Ser 1177 by Akt. The 
generated NO then modulates activity of l-type Ca2+ channels via 
cGMP-sensitive phosphorylation and S-nitrosylation. Along with 
the Ca2+ release from the sarcoplasmic reticulum and SERCA2A the 
calcium pump is activated in response to stimulation of iNOS by 
Epo (166, 167). The exact molecular mechanisms of the action of 
Epo on calcium dynamics in the heart tissue are still unknown, 
however in myocardial stripes and in isolated cells (not on the ves-
sels) they were tracked down to the PI3K-sensitive activation of 
PKCe (141). Stabilization of mitochondrial function in ischemic/
injured myocardium by Epo is mediated by the activation of the 
mitochondrial KATP channels by Epo (166, 167). Furthermore, 
uncoupling of the mitochondrial electron transduction chain is 
reduced due to the interaction of iNOS-derived NO with the mito-
chondrial cytochromes. Mitochondrial biogenesis in cardiomyo-
cytes is promoted by Epo which in turn induces enhancement of 
nuclear respiratory factor-1, PGC-1a (peroxisome proliferator-
activated receptor ϒ coactivator 1a), and mitochondrial transcription 
factor-A gene expression in wild-type but not in eNOS−/− or 
Akt1−/− mice (168). Thus till now, most of the cardioprotective 
effects of Epo interaction with its receptor in cardiomyocytes seem 
to be mediated via PI3K-Akt-eNOS pathway (see Fig. 1).
Systemic induction of endogenous Epo production and release 
is known to occur in response to hypoxic stimulation. All the above 
mentioned responses of heart to Epo increase the survival proba-
bility during injury.
Long-term activation of PI3K/Akt pathways in the heart induces 
activation of insulin-like growth factor binding protein-5 and 
downregulates peroxisome proliferator activated receptor-ϒ 
(PPAR-ϒ) coactivator-1 shifting metabolism from oxidative to 
aerobic glycolytic during long-term ischemia (169). Similar repro-
gramming of metabolism was observed in hypoxic heart and dur-
ing pathological hypertrophic remodeling (170). Glucose delivery 
in cardiac myocytes is up-regulated accordingly as expression of 
Glut4 glucose transporter is induced along with metabolic repro-
gramming (171). Whether long term Epo treatment causes simi-
lar effects remains unclear. Epo binding to its receptors induces 
6.3.2 Chronic 
Responses: Changes  
in Gene Expression
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phosphorylation of Akt and eNOS - its effects are seen within 
5 min (147) and can be observed for the ﬁrst hour and thereafter 
the Epo-EpoR complex is internalized and degraded (Mihov, 
Tavakoli, Bogdanova unpublished observations). The internaliza-
tion rate constant for Epo-EpoR complex in UT-7/Epo cells is 
0.06 min−1 (172). Upon internalization 60% of Epo gets dissoci-
ated from the classical EpoR homodimer and recycled, whereas 
40% undergoes degradation (172). This observation suggests the 
effect of Epo is transient with the amount of surface-based recep-
tors decreasing upon interaction with the cytokine.
Recent trials were performed in which very high doses of Epo were 
administered percutaneously in patients after they were diagnosed 
for myocardial infarction. The expected cardioprotective effects 
included pro-angiogenic, anti-inﬂammatory, anti-apoptotic, and 
anti-oxidative action of Epo which have been reported in animal 
models of myocardial infarction (173–175). However these trials 
showed no beneﬁcial effects of Epo, and in several cases an increase 
in mortality and morbidity was observed due to an increased risk of 
thrombosis (176–179).
Possible reasons for the lack of Epo effect include the inadequate 
root of the cytokine administration (intravenous vs. intramyocardial 
vs. intraperitoneal vs. subcutaneous); lack of cofactors and ligands of 
NO synthases (l-arginine, tetrabiopterin, oxygen) (180–182) and a 
limited “window of cardioprotective effect,” which was claimed to be 
wide, but has never been properly determined in the heart. Epo-
induced activation of NOSes in their uncoupled mode, due to the 
shortage of substrates and cofactors, turns these enzymes from cardio-
protective anti-oxidative ones to cardiotoxic and pro-oxidative (181, 
183, 184). Ischemia-reperfusion of coronary vessels is associated with 
activation of arginase-1 in the endothelium and local reduction in 
arginine availability (185). Oxygen deprivation inhibits eNOS and 
nNOS since their afﬁnity to this substrate is rather low (186).
As the outcome of the ﬁrst Epo trials appeared to be so dis-
couraging an alternative approach has been suggested to increase 
the cytokine efﬁcacy. Cardioplegic solutions widely used in cardiac 
surgery to cause heart arrest are now designed to induce activation 
of endogenous Epo production in the arrested organ (187).
Epo deﬁciency and higher incidence of anemia in individuals with 
diabetes gave the ﬁrst inkling of potential beneﬁcial effects and 
therapeutic applications of Epo use in the diabetes setting. Several 
clinical studies reported a beneﬁcial effect of recombinant Epo on 
glucose metabolism in patients undergoing hemodialysis. Epo 
treatment of patients with end-stage renal disease corrected lipid 
6.4 Epo in Treatment 
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abnormalities and increased insulin sensitivity, with the duration of 
the treatment positively correlating with insulin sensitivity in these 
patients (188–190).
To date Epo expression by pancreatic cells has not been 
observed. However EpoR was expressed on islets of both human 
and non-human primates following Epo supplementation, or after 
transduction with an Adenoviral vector expressing high levels of 
Epo, affording protection of the islets from cytokine-induced 
destruction (49, 191). In addition, performance assessment of 
transduced islets transplanted into diabetic immunodeﬁcient mice 
showed that overexpression of Epo conferred a functional advan-
tage (191) and is also associated with a decrease in body weight 
(192). A number of in vitro and in vivo papers have now provided 
evidence that Epo is beneﬁcial for b cell survival. In NIT-1 pancre-
atic cells, the PI3K inhibitor LY294002 abrogated the anti-apop-
totic activity of Epo, indicating that activation of Akt was required 
for Epo-induced inhibition of cytokine-induced apoptosis (see 
Fig. 1) (193). In another study upregulation of Bcl-2, and con-
comitant downregulation of Bax and caspase 3, has also been sug-
gested as a mechanism through which Epo can protect neonatal 
islet cells. In vivo diabetic rodent models also advocate direct 
effects of Epo on pancreatic b cells (see Fig. 2, pathway 6) promot-
ing anti-apoptosis, proliferation, and angiogenesis signaling 
through its cognate receptor and downstream effector, JAK2, thus 
increasing b-cell mass (194). A very recent study administering a 
single dose of the novel Epo receptor agonist CNTO 530 to diet-
induced obese mice resulted in improved glucose tolerance and 
insulin sensitivity at least in part from increased uptake of glucose 
by skeletal and cardiac muscle (195). The molecular mechanism(s) 
responsible for translating Epo receptor signaling into improved 
glucose tolerance are yet to be revealed and much more data is 
required to better understand its beneﬁcial mechanism of action in 
general. However it is clear that Epo-induced pathways involving 
JAK2, Akt phosphorylation, and altered expression of several 
downstream apoptosis-related proteins, such as Bcl-2 and Bax as 
seen in other tissues, are likely to be a recurrent theme.
Epo was shown to act on endothelial cells in vivo and in vitro 
having growth and chemotactic effects (40). In fact it has been 
suggested that many of the observed non-erythroid cytoprotec-
tive effects of Epo are mediated by second messengers released 
from endothelial cells (see Fig. 2) (196). The observation that 
development of the conditional non-hematopoietic EpoR knock-
out mouse is normal further supports this view. Equally impor-
tant, Epo has been shown to facilitate vascular repair and thereby 
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to improve blood supply to the injured organs by acting on 
endothelial progenitor cells (EPCs; Fig. 2, pathway 5) (196). 
CD34+/Flk-1 (also known KDR or VEGFR2) positive cells are 
hematopoietic progenitor cells that may differentiate into 
endothelial cells and contribute to neovascularization and vascu-
lar repair (197, 198). Epo promotes proliferation (40, 196), 
inhibits apoptosis (199), and facilitates differentiation of EPCs 
(200–203). Furthermore, Epo induces mobilization of EPCs into 
the circulation (204, 205), and their homing (155, 206, 207). 
Increased eNOS expression and BH4 biosynthesis has been 
shown in Epo-treated EPCs and vascular cells (Fig. 2; pathway 4) 
(205, 208). Interestingly, recent studies on hypoxic endothelial 
cells have shown that VEGFR2 can also become an additional com-
ponent for the EpoR/bCR complex that is essential for NO pro-
duction (reviewed by ref. 75). Similar to other non-hematopoietic 
cells PI3K/Akt signaling cascades, induction of mitogen-activated 
protein kinase (MEK)/extracellular signal regulated kinase (ERK) 
signaling pathways (83, 147) and NO production are known to 
mediate Epo effects in endothelial cells in animal models and 
humans patients (see Figs. 1 and 2, pathway 1).
Thus indeed augmented endothelial function may play a major 
role in Epo-mediated protection in non-hematopoietic cells and 
underlie a signiﬁcant amount of tissue recovery from injury. 
Certainly more research needs to be carried out regarding this pos-
sibility and the consequences for the future use of Epo as a treat-
ment strategy.
Although Epo is considered a clinically safe-to-use drug (due to its 
long term use by anemic patients), a number of worrying risks have 
been associated with its more general use as a therapeutic. The 
frequent use of Epo mimetics in patients with chronic kidney dis-
ease (CKD) has recently declined as randomized trials demon-
strated increased incidence of cardiovascular complications and 
mortality without a marked beneﬁt in quality of life (reviewed by 
ref. 209). Safety concerns were raised during treatment of anemia 
in diabetic patients with CKD when they showed a twofold higher 
risk of stroke, an increased risk of venous thromboembolism and 
cancer-related deaths (210). Several studies have suggested that 
exposure to high doses of Epo mimetics, when needed to achieve 
higher hemoglobin levels, is harmful and explains this phenome-
non (211, 212). Very high doses of Epo, in conjunction with 
hypoxia, has also been associated with a paradoxical neurotoxic 
effect suggesting dose–response conditions need to be optimized. 
In the clinics there are also considerable concerns about potential 
thrombotic complications. Recent trials in which very high doses 
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of Epo were administered to patients diagnosed with myocardial 
function showed an increased risk of thrombosis (176–179). 
Thrombotic events were also increased in critical ill patients 
although Epo therapy signiﬁcantly reduced mortality particularly 
in trauma patients (213), and increased risk of venous thromboem-
bolism was also noted in cancer patients (214). Another trial pro-
vided evidence of a possible negative interaction between short-term 
administration of Epo and aspirin due to its ability to modulate 
endothelial activation and platelet reactivity, von Willebrand factor 
antigen levels and factor VIII activity (215, 216). Although largely 
shown to improve neurodevelopmental outcome for preterm 
infants, Epo has been associated with a signiﬁcant increase in the 
rate of retinopathy and may increase hypertension, coagulation, 
and even interfere with neuronal development in neonates 
(reviewed by ref. 84). Finally the therapeutic use of Epo in cancer 
patients remains highly controversial. A number of trials have 
shown that Epo treatment increases the risk for progressive disease 
and death although this may be dependent on the type and stage 
of the cancer (reviewed by ref. 217, 218). Potentially Epo could 
have a direct growth-promoting effect on cancer cells as they have 
been shown to express EpoR.
Thus it is apparent that our knowledge of the Epo signaling 
cascade needs to be signiﬁcantly improved to be able to harness the 
beneﬁts of using Epo and its mimetics as treatment for injury and 
disease. To a great extent its beneﬁcial effects seem to be related to 
timing (the so-called “therapeutic window of opportunity”), dose 
and type of injury. A better understanding of these parameters 
would bring us signiﬁcantly forward in our quest.
A wealth of preclinical data shows that the Epo signaling cascade is 
an important mediator of protection and cell survival in many dif-
ferent non-hematopoietic tissues as part of an innate response to 
injury. Many similarities exist between the mechanisms underlying 
its hematopoietic and non-hematopoietic functions but there are 
also some key differences that functionally lead to distinct outcomes. 
Not unexpectedly it was thought that Epo, a drug considered 
clinically safe, would be a trump card in most injury paradigms, 
however to date results from patient trials have been varied and 
more recently tip the balance to being negative. However, the 
pleiotropic and potentially beneﬁcial biological effects of Epo sig-
naling in non-hematopoietic tissues warrants in depth investiga-
tions of new therapeutic protocols. Clearly the generation of Epo 
mimetics such as asialo-Epo, CEPO, and others that are non-
erythropoietic derivatives (75, 79, 149) will be instrumental in 
providing new options for treatment.
10 Conclusions and Outlook: What Don’t We Know?
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There are perhaps many things we do not yet know that need 
to be considered before being able to reliably use Epo and/or its 
derivatives as therapeutic drugs in different disease paradigms. For 
example what are the relative contributions of endogenous derived 
Epo and EpoR compared to exogenous recombinant Epo that is 
administered therapeutically? Do multiple tissue-speciﬁc Epo or 
EpoR isoforms exist? Is the endogenous balance between pro- and 
anti-apoptotic elements differentially altered by exogenous deriva-
tives and how? What are the side effects of using low or high doses 
of Epo in terms of signaling pathways and negative outcomes? Can 
the Epo/EpoR axis be targeted clinically for therapeutic interven-
tion in a cell or tissue-speciﬁc manner? What is the therapeutic 
window for treatment considering the receptor may not always be 
active? Is the route of administration critical to outcome? Can we 
prime the tissue before treatment or stimulate endogenous Epo 
production? And so on. The list is very long because we do not yet 
know enough about the non-hematopoietic mechanisms of Epo/
EpoR in different tissues, or the short- and/or long-term effects of 
modulating the system
As more research is performed and new therapeutic applica-
tions for Epo are explored, careful consideration of potential 
adverse effects will need to be factored into the design of prospec-
tive clinical studies. Clearly to effectively harness the promise of 
Epo—an old but now pleiotropic growth factor—questions such 
as these need to be addressed now.
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